Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLBI (interferon alpha) plus SMP-275 (ribavirin) in chronic hepatitis C
jRCT2080220092Phase 3
- Sponsor
- Sumitomo Pharma
- Start
- Sep 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ribavirin in hepatitis C virus infection, sponsored by Sumitomo Pharma.
02
Drugs
ribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on jRCT2080220092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220092.